Taiwan Advance Bio-Pharmaceutical Inc. (4186) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Taiwan Advance Bio-Pharmaceutical Inc. stock TWD 6.12, price TWD 6.72, that is 8.9% below the price, quality 51 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
11‑month range 6.70 TWD – 12.50 TWD · fair‑value band 4.66 TWD – 8.22 TWD · the 6.72 TWD price screens above the 6.12 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Taiwan Advance Bio-Pharmaceutical in your weekly email
Every Wednesday you see whether Taiwan Advance Bio-Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally.
Show moreShow less
The company provides food safety diagnostic testing kits; ELISA, rapid, and chemical test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and polyclonal antibody products.
It also offers abused drugs rapid tests; provides cell banking services for newborn and adult stem cells storage; and operates drug testing center for urine drug test, hair drug test, and identification of drug abuse. The company was founded in 1989 and is based in Taipei, Taiwan.
Stock analysis
Taiwan Advance Bio-Pharmaceutical Inc. (4186) currently trades at 6.72 TWD, while our model-based Fair Value estimate is 6.12 TWD, so the stock looks roughly fairly valued today (gap 9.8%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 6.79 TWD per share, and 8 of the 24 models we run sit above the 6.72 TWD price.
Bear case: the Asset-Based group reads lowest at 2.12 TWD, and 16 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 4.66 TWD (bear) to 8.22 TWD (bull), the price of 6.72 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Taiwan Advance Bio-Pharmaceutical Inc. reported revenue of 365M TWD in FY2025 versus 243M TWD in FY2021, a compound +10.6%/yr. Reported net income was 28.0M TWD in FY2025.
Key figures
Market cap 672M TWD (≈ $20.5M) Micro · P/E ratio 39.5 · P/S ratio 1.93 · EPS (TTM) 0.1700 TWD · Net margin 4.5% · Return on equity 6.1% · Return on assets (EBIT) −0.2% (5-year average) · Operating margin −8.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −9%, 4186 screens richer than that median.
Fair Value models
Bear4.66 TWDFair Value 6.12 TWDBull8.22 TWD
Price 6.72 TWD · Downside -8.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1458 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−38.5% (2020) → 10.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +18.0% a year for the price.
Compare Taiwan Advance Bio-Pharmaceutical Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Above median
Fair Value upside−8.9% · Above median
Profitability
Return on equity (12 months)6.1% · Top 25%
Return on assets3.8% · Above median
Net margin (12 months)4.5% · Below median
Operating margin (12 months)−8.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)−9.6% · Below median
Balance sheet
Debt / equity0.22× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)39.5× · Pricier than median
P/B2.36× · Pricier than median
P/S (12 months)1.93× · Cheapest 25%
Price / free cash flow (fiscal year)34.0× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Taiwan Advance Bio-Pharmaceutical Inc. Fair Value". https://www.fairvalue-calculator.com/stock/4186
Frequently asked questions
Is Taiwan Advance Bio-Pharmaceutical Inc. (4186) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 6.12 TWD versus a price of 6.72 TWD, about 9% lower (fairly valued).
What is the fair value of 4186?
Our model-based fair value for Taiwan Advance Bio-Pharmaceutical Inc. is 6.12 TWD (as of Nov 7, 2026), built from audited fundamentals. The current price: 6.72 TWD.
What is the quality score of 4186?
Taiwan Advance Bio-Pharmaceutical Inc. has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
Our model-based price target is the fair value of 6.12 TWD (as of Nov 7, 2026) from 24 valuation models. Cautious scenario 4.66 TWD, optimistic scenario 8.22 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Taiwan Advance Bio-Pharmaceutical Inc. stock forecast for 2026?
Our models put fair value at 6.12 TWD, about 9% lower versus a price of 6.72 TWD (fairly valued). Cautious scenario 4.66 TWD, optimistic scenario 8.22 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
Taiwan Advance Bio-Pharmaceutical Inc. reported trailing-twelve-month revenue of about 349M TWD (latest available figure, as of Nov 7, 2026).
What growth is priced into Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
For today's price to be fair in a discounted-cash-flow model, Taiwan Advance Bio-Pharmaceutical Inc. would have to grow free cash flow by +19.8 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.1 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 4186 use?
Our models discount Taiwan Advance Bio-Pharmaceutical Inc. at 9.0 %: a base by market capitalisation (nano), damped by beta 0.32, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Taiwan Advance Bio-Pharmaceutical Inc. that is +19.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Taiwan Advance Bio-Pharmaceutical Inc. (4186) delivered so far?
Over the past 5 years revenue at Taiwan Advance Bio-Pharmaceutical Inc. grew +9.1 % a year. The price currently implies free-cash-flow growth of +19.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Taiwan Advance Bio-Pharmaceutical Inc. (4186) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Taiwan Advance Bio-Pharmaceutical Inc. (+19.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
The free-cash-flow yield on the price is 3.27 %: that much free cash flow Taiwan Advance Bio-Pharmaceutical Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Taiwan Advance Bio-Pharmaceutical Inc. it is 6.12 TWD per share (as of Nov 7, 2026), against a price of 6.72 TWD. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Taiwan Advance Bio-Pharmaceutical Inc. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 4186 trades above its calculated fair value: price 6.72 TWD, fair value 6.12 TWD, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4186?
No. The price is what the market pays today (6.72 TWD); the fair value is what the company's own numbers justify (6.12 TWD). For Taiwan Advance Bio-Pharmaceutical Inc. the two are 0.6000 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Taiwan Advance Bio-Pharmaceutical Inc. worth?
The market values Taiwan Advance Bio-Pharmaceutical Inc. at about 672M TWD (market capitalisation, as of Nov 7, 2026). Per share that is 6.72 TWD; our models calculate a fair value of 6.12 TWD per share.
What do the bullish and bearish scenarios say about 4186?
Our models span a range for Taiwan Advance Bio-Pharmaceutical Inc.: cautious scenario 4.66 TWD, base 6.12 TWD, optimistic 8.22 TWD per share (as of Nov 7, 2026, price 6.72 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4186?
Taiwan Advance Bio-Pharmaceutical Inc. trades at a price-to-earnings ratio of 39.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 6.12 TWD is built from several models across several years. Other multiples: P/B 2.4, P/S 1.9, EV/EBITDA 14.5.
How solid is the balance sheet of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
Balance-sheet figures for Taiwan Advance Bio-Pharmaceutical Inc. (as of Nov 7, 2026): return on equity 6.1%, debt of 0.22 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 4186 from its 52-week high?
Taiwan Advance Bio-Pharmaceutical Inc. trades at 6.72 TWD, about 46% below its 52-week high of 12.50 TWD and at the low of 6.70 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 6.12 TWD is for.
Which stocks are comparable to Taiwan Advance Bio-Pharmaceutical Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Taiwan Advance Bio-Pharmaceutical Inc. stock attractive at the current price?
The data as of Nov 7, 2026: price 6.72 TWD, calculated fair value 6.12 TWD (−9%), Quality Score 51/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4186 calculated?
We run Taiwan Advance Bio-Pharmaceutical Inc. through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 6.12 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Taiwan Advance Bio-Pharmaceutical Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
The closing price on Nov 6, 2026 was 6.72 TWD. Our model-based fair value is 6.12 TWD, about 9% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Taiwan Advance Bio-Pharmaceutical Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Taiwan Advance Bio-Pharmaceutical Inc.
How large is the market capitalisation of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
The market capitalisation of Taiwan Advance Bio-Pharmaceutical Inc. is 672M TWD (≈ $20.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
The price-to-sales ratio of Taiwan Advance Bio-Pharmaceutical Inc. is 1.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
Earnings per share at Taiwan Advance Bio-Pharmaceutical Inc. are 0.1700 TWD (price ÷ EPS = P/E 39.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
The net margin of Taiwan Advance Bio-Pharmaceutical Inc. is 4.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
The return on equity (ROE) of Taiwan Advance Bio-Pharmaceutical Inc. is 6.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
On an EBIT basis the return on assets of Taiwan Advance Bio-Pharmaceutical Inc. is −0.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
The operating margin of Taiwan Advance Bio-Pharmaceutical Inc. is −8.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
Revenue at Taiwan Advance Bio-Pharmaceutical Inc. is growing −9.6% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Taiwan Advance Bio-Pharmaceutical Inc. (4186)?
Earnings per share at Taiwan Advance Bio-Pharmaceutical Inc. are growing +18.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Taiwan Advance Bio-Pharmaceutical Inc. (4186) carry?
The net debt of Taiwan Advance Bio-Pharmaceutical Inc. is 126M TWD (fiscal year 2025, ≈ 6.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Taiwan Advance Bio-Pharmaceutical Inc. in the live analysis
One click puts Taiwan Advance Bio-Pharmaceutical Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026